基于受累同侧锁骨上淋巴结分布绘制的乳腺癌锁骨上区个体化临床靶区
该研究回顾分析了1998年至2022年209例非转移性乳腺癌伴活检证实的锁骨上淋巴结受累患者的1242枚淋巴结分布,发现相当比例淋巴结位于胸锁乳突肌外侧和前斜角肌背侧,超出RTOG图谱边界,ESTRO上界亦不能保证覆盖,淋巴结大小和分子分型与分布范围相关,作者提出基于情况的个体化临床靶区设想。
要点
- 209例患者1242枚锁骨上淋巴结中,至少537枚(43.2%)位于胸锁乳突肌外侧,403枚(32.4%)位于前斜角肌背侧,超出RTOG图谱覆盖。
- 在≤3枚锁骨上淋巴结的88例患者中,至少66枚(39.1%)位于胸锁乳突肌外侧,34枚(20.1%)位于前斜角肌背侧,未被RTOG图谱覆盖。
- 104例患者(49.8%)的432枚淋巴结(34.8%)超出ESTRO图谱上界。
核心结论
- 锁骨上淋巴结倾向于向外侧和背侧扩散并超出RTOG边界,即使在M0期且锁骨上淋巴结≤3枚时亦然。
- ESTRO上界不能保证多枚锁骨上淋巴结的覆盖。
- 淋巴结负荷和非三阴性类型可预测更广泛的扩散。
- 基于情况的临床靶区可能可行,仍需阐明锁骨上淋巴结的扩散路径。
研究设计与样本
- 纳入活检证实锁骨上淋巴结受累且未接受过锁骨上区治疗的M0乳腺癌患者,将锁骨上区空间分区并在原始图像上绘制每枚淋巴结。
- 评估多个图谱边界的地理遗漏并分析影响锁骨上淋巴结分布模式的因素。
主要发现
- 1998年至2022年共209例患者、1242枚锁骨上淋巴结符合条件,患者中位淋巴结数为4枚。
- 至少537枚淋巴结(43.2%)位于147例患者(70.3%)的胸锁乳突肌外侧,403枚淋巴结(32.4%)位于127例患者(60.8%)的前斜角肌背侧。
- 在≤3枚锁骨上淋巴结的88例患者中,至少66枚淋巴结(39.1%)位于40例患者(45.5%)的胸锁乳突肌外侧,34枚淋巴结(20.1%)位于29例患者(33.0%)的前斜角肌背侧。
- 104例患者(49.8%)的432枚锁骨上淋巴结(34.8%)超出ESTRO图谱上界。
- 多因素回归中,原发组淋巴结大小与更宽分布相关,复发组三阴性亚型与更小分布相关。
关键数值与推荐
- 这些位于胸锁乳突肌外侧和前斜角肌背侧的淋巴结未被RTOG图谱覆盖,部分位于Radiotherapy Comparative Effectiveness图谱内。
- 作者设想基于情况的临床靶区:如为序贯扩散,后界可为后斜角肌或更紧缩;否则应达前斜方肌表面。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To map supraclavicular fossa-involved lymph nodes (SCF-LNs) in patients with nonmetastatic breast cancer, evaluate the coverage of widely adopted atlases, and propose modified borders for individualized regional irradiation. METHODS AND MATERIALS: M0 patients with biopsy-proven SCF-LNs who were SCF treatment-naïve were included. The SCF was spatially divided into subregions, with each node mapped on the original images. The geographic misses after the borders of multiple atlases were evaluated and factors affecting SCF-LNs' spread pattern were analyzed. RESULTS: From 1998 to 2022, 209 patients with 1242 SCF-LNs were eligible. Patients had a median of 4 nodes. At least 537 nodes (43.2%) in 147 patients (70.3%) were lateral to the sternocleidomastoid muscle (SCM), and 403 nodes (32.4%) in 127 patients (60.8%) were dorsal to the anterior scalene muscle (ASM). In the 88 patients with ≤3 SCF-LNs, at least 66 nodes (39.1%) in 40 patients (45.5%) were lateral to the SCM, and 34 nodes (20.1%) in 29 patients (33.0%) were dorsal to the ASM. These nodes were not covered by the Radiation Therapy Oncology Group (RTOG) atlas and partly within the Radiotherapy Comparative Effectiveness atlas. One hundred four patients (49.8%) had 432 SCF-LNs (34.8%) beyond the upper border of the European Society for Radiotherapy and Oncology (ESTRO) atlas. In multivariate regression, nodal sizes were associated with wider spread in the primary group. Being triple-negative (TN) subtype was associated with less spread in the recurrent group. Situation-based clinical target volumes (CTVs) were theorized, in which for a sequential spread, the posterior border could be the posterior scalene muscle or even be more constringent; otherwise, it should touch the anterior trapezius surface. CONCLUSIONS: SCF-LNs tend to spread laterally and dorsally beyond the RTOG borders, even in M0 stages with ≤3 SCF-LNs. The ESTRO upper border does not guarantee coverage with multiple SCF-LNs. Nodal burden and non-TN types are predictive of wider dissemination. A situation-based CTV is possibly feasible. Deciphering the SCF-LN spread route is needed.
引用
- Jing H, Tang Y, Wang ZZ, et al. Individualized Clinical Target Volume for Irradiation of the Supraclavicular Region in Breast Cancer Based on Mapping of the Involved Ipsilateral Supraclavicular Lymph Nodes. Int J Radiat Oncol Biol Phys. 2022. PMID: 36368434. doi:10.1016/j.ijrobp.2022.10.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。